BML, Inc.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2024/02/08 | ¥56.40 | ¥47.58 | -15.6% |
| 2023/02/09 | ¥97.00 | ¥76.71 | -20.9% |
| 2018/05/10 | ¥20.28 | ¥20.19 | -0.4% |
| 2017/11/07 | ¥83.81 | ¥43.43 | -48.2% |
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
MFS Series Trust V-MFS International New Discovery Fund
|
997.4K | 0.00% | |
|
HARTFORD MUTUAL FUNDS INC/CT-The Hartford International Value Fund
|
442.8K | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
310.2K | 0.00% | |
|
Putnam Investment Funds-Putnam International Small Cap Fund
|
238.2K | 0.00% | |
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
199.2K | +17.18% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
187.8K | +4.62% |
Dividend History
Updated 2026/08/16| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥65 | -50.0% |
| 2025 | ¥130 | +44.4% |
| 2024 | ¥90 | -10.0% |
| 2023 | ¥100 | -20.0% |
| 2022 | ¥125 | - |
Financial Performance
2026/08/16 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥186,067M | ¥159,462M | ¥137,964M | ¥143,191M |
| Gross Profit | ¥86,951M | ¥61,446M | ¥45,628M | ¥45,861M |
| Operating Income | ¥48,890M | ¥23,937M | ¥9,167M | ¥9,364M |
| Pretax Income | ¥50,364M | ¥24,224M | ¥9,627M | ¥9,791M |
| Net Income | ¥33,741M | ¥15,578M | ¥6,034M | ¥6,263M |
| EPS | ¥832.62 | ¥395.62 | ¥154.74 | ¥160.55 |
| Operating Margin | 26.28% | 15.01% | 6.64% | 6.54% |
| Balance Sheet | ||||
| Total Assets | ¥179,200M | ¥168,943M | ¥170,991M | ¥177,507M |
| Total Equity | ¥116,196M | ¥122,488M | ¥125,864M | ¥129,400M |
| Total Liabilities | ¥63,004M | ¥46,455M | ¥45,127M | ¥48,107M |
| Cash | ¥92,126M | ¥86,521M | ¥74,114M | ¥67,562M |
| Interest-bearing Debt | ¥3,330M | ¥4,150M | ¥5,265M | ¥5,289M |
| Equity Ratio | 64.84% | 72.50% | 73.61% | 72.90% |
| D/E Ratio | 0.03 | 0.03 | 0.04 | 0.04 |
| Cash Flow | ||||
| Operating CF | ¥45,603M | ¥11,742M | ¥14,446M | ¥15,809M |
| Investing CF | -¥7,297M | -¥7,627M | -¥21,137M | -¥16,793M |
| Financing CF | -¥9,828M | -¥9,715M | -¥5,733M | -¥5,426M |
| Free CF | ¥38,518M | ¥5,282M | -¥6,481M | -¥849M |
| Efficiency | ||||
| ROE | 29.04% | 12.72% | 4.79% | 4.84% |
| ROA | 18.83% | 9.22% | 3.53% | 3.53% |
Latest IR Information
-
Notice of Share Buyback as Restricted Stock Unit
Notification of completion of payment for disposal of treasury stock as part of restricted stock units. Total amount 68,909,640 yen, 19,466 shares disposed. Disposals to directors and executive officers, payment date August 21, 2026.
Read more -
2027 Fiscal Year Q1 Consolidated Financial Summary (Japanese GAAP) (Consolidated)
Disclosure of the consolidated results for the first quarter of the 2027 fiscal year. Describes YoY changes in sales and each earnings metric, trends by segment such as clinical testing and medical information systems, and notes on new business wins...
Read more -
Notice of Disposal of Treasury Stock Based on Restricted Stock Compensation System
B.M.L Inc. will dispose of 19,466 common shares under the restricted stock compensation system, raising 68,909,640 yen. The disposal is scheduled for August 21, 2026.
Read more -
Fiscal Year Ending March 2026 Financial Results Summary [Japanese Standards] (Consolidated)
Net sales of 150,262 million yen (up 4.9% YoY), operating income of 10,421 million yen (up 11.3% YoY), and net income attributable to shareholders of 7,748 million yen (up 23.7% YoY) were achieved.
Read more -
【BML】2026 Fiscal Year Dividend Increase｜Raised to 65 Yen in May 2026
BML has resolved to increase the year-end dividend for the fiscal year ending March 2026 to 65 yen per share, with a total dividend amount of 2,436 million yen. The increase reflects the upward revision of consolidated earnings and aligns...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥3,800
Rating Score: 3.00 (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
BML, Inc. provides contract clinical testing and related services in Japan. The company offers routine laboratory testing, such as biochemical and hematologic examination; special laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispensing. It also provides contract clinical testing, including endocrine, plasma protein, biochemical, viral, immunoserological, hematological, cellular immunity, bacteriological, and histopathological, pathological, and cytological tests; specimen receiving service; and medical information system services, which include electronic medical charts for clinics without beds. In addition, the company is involved in manufacturing and supply services for medical equipment and supplies; real estate leasing and insurance agency business; providing food hygiene inspection and food consulting services; and dispensing pharmacy services. The company was incorporated in 1955 and is headquartered in Tokyo, Japan.
